CRL Stock Analysis: Buy, Sell, or Hold?
CRL - Charles River Laboratories International, Inc.
$344.87
29.42 (9.33%)
▲
5d:
+14.2%
30d:
+20.96%
90d:
+50.41%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When CRL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CRL is 11.3% above its trading range ($309.84). Market expects 15.3% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CRL is 11.3% above its trading range ($309.84). Market expects 15.3% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$331.94
Based on 8.1% avg growth
INTRINSIC VALUE TODAY
$206.11
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRL is currently trading at $344.87, which is considered extended relative to its 30-day fair value range of $279.87 to $309.84. From a valuation perspective, the stock is trading at a premium (Forward PE: 27.0) compared to its historical average (17.7). At these levels, the market is pricing in 15.3% annual earnings growth.
Technical Outlook: Technically, CRL is in a strong uptrend. The price is approaching resistance at $348.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.3% recently.
Market Sentiment: CRL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRL is in a strong uptrend. The price is approaching resistance at $348.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.3% recently.
Market Sentiment: CRL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$279.87 -
$309.84
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
20.0%
All Signals
- BEARISH: Price significantly overextended (+11.3% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.3%)
- BEARISH: Trading above Wall St target ($315.53)
- BULLISH: Expecting earnings turnaround to 15.3% growth with -2.7% revenue growth
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$279.87 -
$309.84
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$288.43
Resistance Level
$348.95
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.04
Wall Street Target
$315.53
(-8.5%)
Revenue Growth (YoY)
-2.7%
Earnings Growth (YoY)
-17.3%
Profit Margin
-6.0%
Valuation Premium vs History
+15.3% premium
PE vs Historical
27.0 vs 17.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.3%
(market-implied from PE analysis)
1-Year Target
$397.64
(+15%)
2-Year Target
$458.47
(+33%)
3-Year Target
$528.62
(+53%)
3-Yr Target (if PE normalizes)
(PE: 27→18)
PE COMPRESSION
$346.08
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.0, Growth: 12.1%)
$486.11
(+41%)
Base:
(SPY PE: 19.9, Growth: 12.1%)
$357.09
(+4%)
Bear:
(PE: 16.9, Growth: 12.1%)
$303.53
(-12%)
Share & Embed Analysis
Last updated: October 22, 2026 8:47 AM ET
Data refreshes hourly during market hours. Next update: 9:47 AM
Data refreshes hourly during market hours. Next update: 9:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$202 | 61 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
28 analysts |
$691 | 42 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$244 | 40 SELL |
|
NTRA
Natera Inc |
STRONG BUY
23 analysts |
$404 | 44 HOLD |
